________________________________________________________
____EntRel____
275
2
____Arg1____
137..273
1
#### Text ####
The patent for Interleukin-3 covers materials and methods used to make the human blood cell growth factor via recombinant DNA technology
##############
____Arg2____
275..430
2
#### Text ####
Sandoz Ltd. has licensed certain manufacturing and marketing rights for Interleukin-3 from Genetics Institute and is conducting preclinical studies with it
##############
________________________________________________________
________________________________________________________
____EntRel____
432
3
____Arg1____
275..430
2
#### Text ####
Sandoz Ltd. has licensed certain manufacturing and marketing rights for Interleukin-3 from Genetics Institute and is conducting preclinical studies with it
##############
____Arg2____
432..604
3
#### Text ####
Interleukin-3 may help in treating blood cell deficiencies associated with cancer treatment, bone marrow transplants and other blood-cell disorders, Genetics Institute said
##############
________________________________________________________
________________________________________________________
____Implicit____
722
5
#### Features ####
Wr, Comm, Null, Null
specifically, Expansion.Restatement.Specification
____Arg1____
608..720
4
#### Text ####
The second patent describes bone morphogenetic protein-1, a substance that can induce formation of new cartilage
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
722..842
5,0
#### Text ####
The patent covers BMP-1 type proteins and pharmaceutical compositions and methods for treating bone or cartilage defects
##############
#### Features ####
Ot, Comm, Null, Null
844..867
5,1;5,2;5,3;5,4
#### Text ####
Genetics Institute said
##############
________________________________________________________
________________________________________________________
____EntRel____
869
6
____Arg1____
722..867
5
#### Text ####
The patent covers BMP-1 type proteins and pharmaceutical compositions and methods for treating bone or cartilage defects, Genetics Institute said
##############
____Arg2____
869..1023
6
#### Text ####
The company added that it has filed patent applications "on a large number of different BMP proteins" and the patent on BMP-1 is the first it has received
##############
________________________________________________________
________________________________________________________
____Explicit____
971..974
6,1
#### Text ####
and
##############
#### Features ####
Ot, Comm, Null, Null
869..886
6,0,0;6,0,1,0
#### Text ####
The company added
##############
and, Expansion.Conjunction
____Arg1____
887..969
6,0,1,1
#### Text ####
that it has filed patent applications "on a large number of different BMP proteins
##############
#### Features ####
Inh, Null, Null, Null
____Arg2____
975..1023
6,2
#### Text ####
the patent on BMP-1 is the first it has received
##############
#### Features ####
Inh, Null, Null, Null
________________________________________________________
________________________________________________________
____EntRel____
1025
7
____Arg1____
869..1023
6
#### Text ####
The company added that it has filed patent applications "on a large number of different BMP proteins" and the patent on BMP-1 is the first it has received
##############
____Arg2____
1025..1171
7
#### Text ####
BMP products may be useful in fracture healing and in treating bone loss associated with periodontal disease and certain cancers, the company said
##############
________________________________________________________
